Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19178769 | CONDITIONAL MULTICAPITATE NEURAL NETWORKS FOR AI-BASED PROTEIN AND DRUG DESIGN | April 2025 | August 2025 | Allow | 4 | 3 | 0 | Yes | No |
| 18874453 | SYSTEMS AND METHODS FOR IDENTIFYING PEPTIDES BY SAMPLING AND FILTERING | December 2024 | January 2026 | Allow | 13 | 2 | 0 | Yes | No |
| 18740810 | UNIFORM RESOURCE IDENTIFIER ENCODING | June 2024 | December 2025 | Allow | 18 | 3 | 0 | Yes | No |
| 18434510 | HLA Tissue Matching And Methods Therefor | February 2024 | February 2026 | Allow | 24 | 0 | 0 | Yes | No |
| 18540814 | Method for the Compression of Genome Sequence Data | December 2023 | October 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18230296 | CHEMICAL METHODS FOR NUCLEIC ACID-BASED DATA STORAGE | August 2023 | February 2026 | Abandon | 30 | 4 | 0 | Yes | No |
| 18340792 | METHODS AND SYSTEMS FOR ANALYZING NUCLEIC ACID SEQUENCES | June 2023 | March 2026 | Abandon | 33 | 1 | 0 | No | No |
| 18128557 | TECHNIQUES FOR MODELLING AND OPTIMIZING DIALYSIS TOXIN DISPLACER COMPOUNDS | March 2023 | December 2025 | Allow | 33 | 1 | 0 | Yes | No |
| 17963665 | IDENTIFICATION OF CLONAL NEOANTIGENS AND USES THEREOF | October 2022 | October 2025 | Allow | 36 | 3 | 0 | Yes | No |
| 17946901 | DYNAMIC DATA SET MODIFICATION AND MAPPING | September 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17888439 | GENOTYPING POLYPLOID LOCI | August 2022 | August 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17804416 | COMPARATIVELY-REFINED POLYGENIC RISK SCORE GENERATION MACHINE LEARNING FRAMEWORKS | May 2022 | February 2026 | Allow | 45 | 0 | 0 | No | No |
| 17763401 | METHOD AND SYSTEM FOR PERFORMING NON-INVASIVE GENETIC TESTING USING AN ARTIFICIAL INTELLIGENCE (AI) MODEL | March 2022 | November 2025 | Allow | 43 | 0 | 0 | Yes | No |
| 17654520 | MODELING THE CHEMICAL COMPOSITION OF A BIOLOGICAL CELL WALL | March 2022 | March 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17456519 | Network Medicine Framework for Identifying Drug Repurposing Opportunities | November 2021 | January 2026 | Allow | 50 | 1 | 0 | No | No |
| 17534542 | Method for analyzing relationship between communication path and heat resistance of lipase | November 2021 | February 2026 | Abandon | 50 | 1 | 0 | No | No |
| 17530484 | INTRADIALYTIC ANALYSIS METHOD AND ANALYSIS APPARATUS FOR DIALYSIS | November 2021 | January 2026 | Allow | 50 | 2 | 0 | Yes | No |
| 17484179 | GENE SIGNATURES FOR CANCER PROGNOSIS | September 2021 | November 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17482405 | Machine-Learned Quality Control for Epigenetic Data | September 2021 | October 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17361781 | ANTIMICROBIC SUSCEPTIBILITY TESTING USING MACHINE LEARNING | June 2021 | August 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17361827 | METHODS OF PREDICTING AGE, AND IDENTIFYING AND TREATING CONDITIONS ASSOCIATED WITH AGING USING SPECTRAL CLUSTERING AND DISCRETE COSINE TRANSFORM | June 2021 | September 2025 | Abandon | 51 | 1 | 0 | No | No |
| 17349851 | BIOLOGICAL KIN RECOGNITION METHOD AND SYSTEM BASED ON UNSUPERVISED CLUSTERING OF mRNA BASE | June 2021 | August 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17349830 | METHODS AND SYSTEMS FOR DETECTING GENETIC FUSIONS TO IDENTIFY A LUNG DISORDER | June 2021 | July 2025 | Abandon | 49 | 1 | 0 | Yes | No |
| 17296654 | METHOD FOR DETECTING AND MONITORING THE FORMATION OF BIOFILMS | May 2021 | March 2025 | Abandon | 46 | 0 | 0 | No | No |
| 17320324 | PREDICTING CHANGES IN MEDICAL CONDITIONS USING MACHINE LEARNING MODELS | May 2021 | February 2026 | Abandon | 57 | 3 | 0 | No | No |
| 17291224 | PREDICTIVE METHODS IN BREAST CANCER | May 2021 | January 2026 | Abandon | 56 | 2 | 0 | No | No |
| 17290924 | ENHANCED DETECTION OF TARGET DNA BY FRAGMENT SIZE ANALYSIS | May 2021 | April 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17243473 | VIRTUALLY MONITORING BLOOD PRESSURE LEVELS IN A PATIENT USING MACHINE LEARNING AND DIGITAL TWIN TECHNOLOGY | April 2021 | November 2025 | Allow | 55 | 3 | 0 | Yes | No |
| 17195339 | CODES TO DETECT INSERTION AND DELETION ERRORS IN A DENSE STORAGE MEDIUM | March 2021 | April 2025 | Allow | 49 | 0 | 0 | Yes | No |
| 17172668 | METHOD AND APPARATUS FOR PREDICITING NEUROLOGICAL OUTCOME POST-CARDIAC ARREST | February 2021 | July 2025 | Allow | 53 | 2 | 0 | Yes | No |
| 16972458 | MULTI-DOMAIN PROTEINS WITH INCREASED NATIVE STATE COLLOIDAL STABILITY | December 2020 | February 2025 | Allow | 50 | 2 | 0 | No | No |
| 17058981 | LIPID NANOTABLET | November 2020 | March 2025 | Allow | 52 | 1 | 0 | No | No |
| 16890542 | DATABASE SNAPSHOT AND BACKUP MANAGEMENT WITH RECOVERABLE CHAINS | June 2020 | November 2024 | Allow | 54 | 3 | 0 | Yes | No |
| 16545751 | Systems and Methods for Compressing Genetic Sequencing Data and Uses Thereof | August 2019 | January 2025 | Allow | 60 | 1 | 0 | Yes | No |
| 16534257 | Methods and Systems for Protein Identification | August 2019 | February 2026 | Abandon | 60 | 10 | 1 | Yes | No |
| 16341361 | METHOD AND SYSTEM FOR THE TRANSMISSION OF BIOINFORMATICS DATA | April 2019 | May 2025 | Allow | 60 | 4 | 0 | Yes | No |
| 16019332 | METHODS AND APPARATUSES FOR PREDICTION OF MECHANISM OF ACTIVITY OF COMPOUNDS | June 2018 | May 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 15917419 | BIOPROCESS METHOD AND SYSTEM VIA AUTOMATED LABORATORY SYSTEMS | March 2018 | September 2025 | Abandon | 60 | 8 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FRUMKIN, JESSE P.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FRUMKIN, JESSE P works in Art Unit 1685 and has examined 24 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner FRUMKIN, JESSE P's allowance rate of 50.0% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by FRUMKIN, JESSE P receive 2.33 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by FRUMKIN, JESSE P is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.0% benefit to allowance rate for applications examined by FRUMKIN, JESSE P. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.5% of applications are subsequently allowed. This success rate is in the 29% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 12% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 28.6% are granted (fully or in part). This grant rate is in the 16% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.